Teva Pharmaceutical Industries Limited released its earnings results on Nov 05, 2025. The company reported 254.1 earnings per share for the quarter, beating the consensus estimate of 226.3 by 27.8.

Is Teva Pharmaceutical Industries Limited overvalued?

According to Wall Street analysts Teva Pharmaceutical Industries Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Teva Pharmaceutical Industries Limited pay dividends?

Teva Pharmaceutical Industries Limited pays a Quarterly dividend of 8.5 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical Industries Limited dividends here

What is Teva Pharmaceutical Industries Limited’s EPS estimate?

Teva Pharmaceutical Industries Limited’s EPS estimate is 204.3.

How many shares outstanding does Teva Pharmaceutical Industries Limited have?

Teva Pharmaceutical Industries Limited has 1,146,838,700 shares outstanding.

What happened to Teva Pharmaceutical Industries Limited’s price movement after its last earnings report?

Teva Pharmaceutical Industries Limited reported an EPS of 254.1 in its last earnings report, beating expectations of 226.3. Following the earnings report the stock price went up 17.191%.

Which hedge fund is a major shareholder of Teva Pharmaceutical Industries Limited?

Currently, no hedge funds are holding shares in IL:TEVA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.